Next Phase Newsletter

A healthcare focused fund, headquartered in Shanghai and with a presence in US and Europe is broadly focused in Life Sciences with strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, would like to lead investments and play active roles in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, and ophthalmology related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all opportunities within the early stage, however diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies that they have invested in. Outside of the board requirement, the firm is looking for strong management teams that demonstrate the capability to move their technology forwards.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate venture arm of a bank has a €250M evergreen fund, with about half of their investments in the life sciences. The firm invests primarily during series A-B rounds, but will occasionally invest in seed-stage companies as well, and will follow on in subsequent rounds. The firm invests in medical device, diagnostics and digital health companies, and can invest throughout Europe, but focuses mostly in France. The firm will invest anywhere from €1-20M.

The firm invests in medical devices, diagnostics and digital health technologies. Generally, the firm does not invest in therapeutics companies, nor companies in clinical stages. The firm will usually not invest in companies before they have earned their CE mark, and is generally opportunistic to indication.

The firm will only lead or co-lead investments, and always takes a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the Netherlands is raising a new fund, with a target of over EUR 100 million. The firm invests all over Europe, and the new fund will have the capacity to invest in the US as well. The firm invests up to EUR 12 million, and may make larger investments from the new fund. The firm generally leads financing rounds.

The firm focuses on therapeutic modalities and platforms, including small molecules, antibodies, cell therapies, and screening platforms including genetic screening. The fund is indication agnostic and typically invests at an early stage.

The firm is a very active investor and typically leads rounds, but can also be a follow-on investor. The firm also sometimes takes part in company generation and new spin-outs from universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A venture capital firm based in Taipei makes venture stage investments solely in life sciences companies. The firm is currently investing from a US$35M private fund and a $50M government matching fund. Equity allocation size varies and can reach up to US$3M per deal. The firm is open to leading or co-investing. The firm focuses 30% on foreign deals and is currently seeking new opportunities.

The firm is focused on pharmaceuticals, medical devices, diagnostic products, and medical instruments etc. The firm looks for companies with strong intellectual propositions that will develop unmet medical need products. The firm intends to explore joint venture opportunities with foreign companies that can integrate Taiwan’s competitive capabilities in manufacturing, clinical development, and regional sales/distribution.

The firm is looking for experienced management teams with strong sector expertise. For domestic deals, the firm seeks an active role in its portfolio companies and would require a board seat on a case-by-case basis. For foreign deals, the firm prefers to syndicate with a strong lead that can work with invested companies closely.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A major reinsurance firm based in Europe makes direct venture stage investments in strategically relevant healthcare startups through a corporate venture capital team, and also invests in life science funds and incubators around the world. The firm invests opportunistically, with a focus on early stage opportunities.

The firm invests strategically in startups that could potentially drive growth in its life and health insurance businesses. In life sciences, the firm is interested in the convergence of life science and insurance tech, and invests in areas such as genomics, digital health, and diagnostics (including diagnostic products focused on consumers as users). The firm is open to investing in any indication area.

The firm’s investments are strategic in nature, and the firm can potentially act as a strategic partner to a portfolio company by supporting product deployment among its network in the health insurance space.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A venture capital firm based in Silicon Valley works closely with major incubators globally, through which they are able to identify high-potential, disruptive technologies. The firm is actively investing in early-stage companies and generally participates in Series A to B financing rounds. The initial size of investment depends largely on the company’s stage of development. The firm seeks investments globally.

The firm will consider opportunities in therapeutics, diagnostics, and digital health/healthcare IT. The firm is most interested in data-centric and enterprise technologies. The firm is agnostic to subsector and indication, but the firm will generally avoid medical device companies and early-stage therapeutics companies (i.e. those that take longer than 18 months to commercialize). That said, the firm may consider derisked assets or those that have an accelerated pathway to commercialization. Within healthcare IT technologies, the firm would like to see revenue-generating companies with good consumer traction.

The firm invests in both publicly traded and privately-owned companies. The firm is an active investor and will directly engage in the growth of their portfolio companies through a number of value-ons, including brand building, international expansion, talent recruiting, operation and technical guidance, etc. The firm need not have a fully established management team prior to investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

An investment firm headquartered in China manages three venture capital funds in RMB with a total of 1,400 MM RMB (~200MM USD); the firm is still raising a fund in U.S. dollars of 50MM~100MM USD, with the confirmed limited partners from well-known Chinese big pharma.

The firm has 24 portfolio companies, and is open to investing globally in the angel to series B round, with a focus on series A round. For therapeutics, the firm is interested in pre-clinical to phase III, mainly the pre-clinical stage. For each fund, the firm selects 10-15 companies to invest, and each investment ranges from 10MM RMB (1,420,000 USD) to 40MM RMB (5,700,000 USD); the rest of the fund will be used to invest the follow-on rounds of those selected companies to help them grow.

The firm has a general interest in the early-stage life science technology assets, including therapeutics, diagnostics, medical devices, and digital health, especially MRA, gene diagnostics, AI in healthcare, cell/gene therapy. The firm prefers projects in novel developing areas, but has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm has no specific requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.